RELMADA THERAPEUTICS INC's ticker is RLMD and the CUSIP is 75955J402. A total of 118 filers reported holding RELMADA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $97,635 | +22.0% | 32,545 | 0.0% | 0.00% | +33.3% |
| Q2 2023 | $80,061 | +8.8% | 32,545 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $73,552 | -35.2% | 32,545 | 0.0% | 0.00% | -40.0% |
| Q4 2022 | $113,582 | -90.6% | 32,545 | 0.0% | 0.01% | -91.1% |
| Q3 2022 | $1,205,000 | +95.0% | 32,545 | 0.0% | 0.06% | +107.4% |
| Q2 2022 | $618,000 | -29.6% | 32,545 | 0.0% | 0.03% | -20.6% |
| Q1 2022 | $878,000 | +19.8% | 32,545 | 0.0% | 0.03% | +25.9% |
| Q4 2021 | $733,000 | -1.5% | 32,545 | +14.7% | 0.03% | -12.9% |
| Q3 2021 | $744,000 | -18.1% | 28,378 | 0.0% | 0.03% | -13.9% |
| Q2 2021 | $908,000 | -9.1% | 28,378 | 0.0% | 0.04% | -12.2% |
| Q1 2021 | $999,000 | -30.9% | 28,378 | -37.0% | 0.04% | -36.9% |
| Q4 2020 | $1,445,000 | +35.3% | 45,044 | +58.7% | 0.06% | +20.4% |
| Q3 2020 | $1,068,000 | -15.9% | 28,378 | 0.0% | 0.05% | -20.6% |
| Q2 2020 | $1,270,000 | +31.2% | 28,378 | 0.0% | 0.07% | +15.3% |
| Q1 2020 | $968,000 | -18.3% | 28,378 | -6.6% | 0.06% | +3.5% |
| Q4 2019 | $1,185,000 | – | 30,378 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,270,072 | $61,269,000 | 9.93% |
| GREAT POINT PARTNERS LLC | 790,000 | $21,322,000 | 5.15% |
| ACUTA CAPITAL PARTNERS, LLC | 342,000 | $9,231,000 | 4.31% |
| COWEN AND COMPANY, LLC | 1,164,361 | $31,426,000 | 3.02% |
| Altium Capital Management LP | 206,000 | $5,560,000 | 1.86% |
| BVF INC/IL | 1,647,400 | $44,463,000 | 1.78% |
| RTW INVESTMENTS, LP | 2,540,074 | $68,557,000 | 1.42% |
| Vivo Capital, LLC | 705,882 | $19,052,000 | 1.31% |
| RA Capital Management | 2,000,000 | $53,980,000 | 1.18% |
| SPHERA FUNDS MANAGEMENT LTD. | 291,252 | $7,861,000 | 1.11% |